Document:

EX-4.4(c)

 Exhibit 4.4(c) 

Execution Version 

SECOND AMENDMENT TO WARRANT AGREEMENT 

THIS SECOND AMENDMENT (this “Amendment”), dated as of May 31, 2019, to the Warrant Agreement to Purchase Shares of
Preferred Stock of Intuity Medical, Inc., originally dated as of December 29, 2017, as amended by the First Amendment to Warrant Agreement, dated as of December 27, 2018 (as amended, the “Warrant Agreement”), is made by
and between INTUITY MEDICAL, INC., a Delaware corporation (the “Company”), and HERCULES CAPITAL, INC., a Maryland corporation (the “Warrantholder”). 

A. The Company and the Warrantholder desire to further amend the Warrant Agreement as set forth herein, such modifications to be effective as
of the date hereof. 
 B. The Warrant may be amended pursuant to Section 12(h) thereof by the written agreement of the Company and the
Warrantholder, each of which is a party to this Amendment. 
 AGREEMENT 

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows: 
 1. Amendments to the Warrant Agreement. The Company and Warrantholder hereby agree to the following amendments to the
Warrant Agreement. 
 (A) The definition of “Equity Round” is hereby amended and restated in its entirety to
read as follows: 
 ““Equity Round” means any non-public offering of equity
securities by the Company, completed after the Effective Date but prior to the consummation of an Initial Public Offering, in a transaction or series of related transactions principally for equity raising purposes in which the cash proceeds are
received by the Company and/or debt of the Company is cancelled or converted in exchange for equity securities of the Company.” 

(B) The definition of “Exercise Price” is hereby amended and restated in its entirety to read as follows: 

““Exercise Price” means (a) if Preferred Stock means the Series 5 Preferred Stock, $0.38 per share, or (b) if
Preferred Stock means Next Round Stock, the lowest cash price per share of Next Round Stock paid by investors in the Next Round, in each case subject to adjustment pursuant to the applicable provisions of this Warrant Agreement.” 

(C) The definition of “Next Round” is hereby amended and restated in its entirety to read as follows: 

 

 ““Next Round” means the next Equity Round after May 31, 2019 in
which the Company issues and sells shares of its preferred stock and any options, warrants, rights or other securities that are exercisable, convertible or exchangeable into, or otherwise provide the right to purchase or acquire shares of preferred
stock of the Company, and that results in aggregate gross cash proceeds of at least $10,000,000 (excluding proceeds from the conversion of any notes or other convertible securities) and the use of such proceeds is primarily for general working
capital purposes; provided, however, a Next Round shall not include the issuance and sale by the Company of Convertible Notes in the Second Tranche Closing (as such terms are defined in that certain Series 5 Preferred Stock, Warrant
and Convertible Note Purchase Agreement, made as of May 2, 2019, by and among the Company and the investors party thereto (the “Series 5 Purchase Agreement”)), pursuant to the Series 5 Purchase Agreement, as such Convertible
Notes may be amended, modified, supplemented or amended and restated from time to time.” 
 (D) The definition of
“Preferred Stock” is hereby amended and restated in its entirety to read as follows: 
 ““Preferred
Stock” means, at the election of the Warrantholder, (a) the Series 5 Preferred Stock or (b) following the closing of the Next Round, the class and series of the preferred stock of the Company and any options, warrants, rights or
other securities that are exercisable, convertible or exchangeable into, or otherwise provide the right to purchase or acquire shares of preferred stock issued in the Next Round (such equity securities, the “Next Round Stock”), and
(c) any other stock into or for which the Preferred Stock may be converted or exchanged.” 
 (E) The definition of
“Warrant Coverage” is hereby amended and restated in its entirety to read as follows: 
 ““Warrant Coverage”
means $296,250.” 
 (F) The following definition of “Series 5 Preferred Stock” is hereby added to
Section 1 of the Warrant Agreement in its proper alphabetical order: 
 ““Series 5 Preferred Stock” means the
Series 5 Convertible Participating Preferred Stock, $0.001 par value per share, of the Company. 
 2. Effect on Warrant Agreement.
Except as specifically amended hereby, the Warrant Agreement shall continue to be in full force and effect and is hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of this Amendment shall not operate as a
waiver of any right, power or remedy of the Warrantholder under the Warrant Agreement, and it does not constitute a waiver of any provision of the Warrant Agreement. 

  
 2 

 3. Capitalized Terms. Capitalized terms that are not otherwise defined in this
Amendment, but that are used herein (including as may be used in the Recitals), shall have the respective meanings given to them in the Warrant Agreement. 

4. Governing Law. This Amendment shall be governed by, and construed in accordance with, the law of the State of California. 

5. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Delivery by facsimile,.pdf or other electronic imaging means of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart
of this Amendment. The Warrantholder may also require that any such documents and signatures delivered by facsimile,.pdf or other electronic imaging means be confirmed by a manually signed original thereof; provided that the failure to
request or deliver the same shall not limit the effectiveness of any document or signature delivered by facsimile,.pdf or other electronic imaging means. 

[Remainder of page intentionally blank] 

  
 3 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment to Warrant Agreement
as of the date first set forth above. 
  

			
	Company:
	
	INTUITY MEDICAL, INC.
		
	By:	 	 /s/ Emory V. Anderson

		 	Name: Emory V. Anderson
		 	Title: President and Chief Executive Officer
	
	Warrantholder:
	
	HERCULES CAPITAL, INC.
		
	By:	 	 /s/ Jennifer Choe

		 	Name: Jennifer Choe
		 	Title: Assistant General CounselEX-4.4(d)

 Exhibit 4.4(d) 

INTUITY MEDICAL, INC. 
 Hercules Capital,
Inc. 
 Legal Department 
 400 Hamilton Avenue, 

Suite 310 
 Palo Alto, CA 94301 

October 30, 2020 
 Re: Warrant Agreement 

Ladies and Gentlemen, 
 Reference is hereby made
to that certain Warrant Agreement by and between Hercules Capital, Inc. (the “Warrantholder”) and Intuity Medical, Inc., a Delaware corporation (the “Company”), dated as of December 29, 2017 (as amended or
modified from time to time, the “Warrant”). Capitalized terms used but not defined herein shall have the meaning ascribed to such term in the Warrant. 

Each of the Company and the Warrantholder hereby acknowledges and agrees that (i) the closing of the sale and issuance by the Company of
New Series B-1 Preferred Stock pursuant to that certain New Series B, B-1, C and C-1 Preferred Stock Purchase Agreement dated
October 15, 2020 by and among the Company and the investors party thereto is deemed to be the Next Round financing under the Warrant, (ii) at such time as the Warrantholder elects to exercise the Warrant, the Preferred Stock, or Next Round
Stock, shall mean the New Series B-1 Preferred Stock, (iii) the Exercise Price shall mean $0.2247 per share of New Series B-1 Preferred Stock (resulting in the
Warrant being exercisable for up to 1,318,424 shares of New Series B-1 Preferred Stock as of the date hereof), and (iv) the Warrantholder will not have any rights to any further election with respect to
the class or series of the Company’s capital stock issuable upon exercise of the Warrant, in each case, subject to the terms and conditions set forth in the Warrant. 

Except as expressly set forth herein, all of the terms, conditions, and provisions of the Warrant shall remain in full force and effect. This
letter agreement is limited precisely as written and shall not be deemed to be an amendment of any other term or condition of the Warrant or any of the documents referred to therein. This letter agreement shall form a part of the Warrant for all
purposes, and each party thereto and hereto shall be bound hereby. Each party hereby represents and warrants to the other party that it has the requisite power and authority to enter into this letter agreement and it has obtained all necessary
consents and approvals necessary and appropriate for such party to fulfill its agreements and obligations hereunder. This letter agreement may be executed in counterparts, including counterparts by pdf. 

[Remainder of page intentionally left blank] 

 
			
	Yours Truly,
	
	Intuity Medical, Inc.
		
	By:	 	 /s/ Tammy Cameron

	Name:	 	Tammy Cameron
	Title:	 	CFO

  

			
	Agreed and accepted by:
	
	Hercules Capital, Inc.
		
	By:	 	 /s/ Jennifer Choe

	Name:	 	Jennifer Choe
	Title:	 	Associate General Counsel

  

  
 [Signature Page to
Letter Agreement]EX-4.5(a)

 Exhibit 4.5(a) 

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL)
REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 

WARRANT AGREEMENT 
 To
Purchase Shares of Preferred Stock of 
 INTUITY MEDICAL, INC. 

Dated as of December 29, 2017 (the “Effective Date”) 

WHEREAS, Intuity Medical, Inc., a Delaware corporation, has entered into a Loan and Security Agreement of even date herewith (the
“Loan Agreement”) with Hercules Capital, Inc., a Maryland corporation, in its capacity as administrative and collateral agent, Hercules Technology III, L.P., a Delaware limited partnership (the “Warrantholder”), and
the other lender parties thereto; and 
 WHEREAS, the Company (as defined below) desires to grant to the Warrantholder, in
consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”). 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial
accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and the Warrantholder agree as follows: 
  

	SECTION 	 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, an aggregate number of fully paid and non-assessable shares of the Preferred Stock equal to the quotient derived by dividing
(a) the Warrant Coverage (as defined below) by (b) the Exercise Price (defined below). The Exercise Price and type of such shares are subject to adjustment as provided in Section 8. As used herein, the following
terms shall have the following meanings: 
 “Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Thirteenth Amended and Restated Certificate of Incorporation, as may be amended from time
to time. 

  
 1 

 “Common Stock” means the Company’s Common Stock, $0.001 par value per
share. 
 “Company” means Intuity Medical, Inc., a Delaware corporation, and any successor or surviving entity that assumes
the obligations of the Company under this Agreement pursuant to Section 8(a). 
 “Exercise Price”
means $0.38 per share, subject to adjustment pursuant to Section 8, subject to adjustment pursuant to Section 8. 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which registration statement has been declared effective by the SEC. 
 “Marketable
Securities” in connection with a Merger Event means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities
Exchange Act of 1934 (as amended, the “1934 Act”), and is then current in its filing of all required reports and other information under the Act and the 1934 Act; (ii) the class and series of shares or other security of the
issuer that would be received by the Warrantholder in connection with the Merger Event were the Warrantholder reports and other information under the Act and the 1934 Act; (ii) the class and series of shares or other security of the issuer that
would be received by the Warrantholder in connection with the Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, and (iii) following the closing of such Merger Event, the Warrantholder would not be restricted from publicly re-selling all of the
issuer’s shares and/or other securities that would be received by the Warrantholder in such Merger Event were the Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event, except to the extent that any such
restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Merger Event. 

“Merger Event” means any sale, lease, exclusive license or other transfer of all or substantially all assets of the Company
or any merger or consolidation involving the Company in which the Company is not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of preferred stock,
other securities or property of another entity. 
 “Preferred Stock” means, the Series 4 Convertible Participating
Preferred Stock, $0.001 par value per share, of the Company, and, to the extent provided in Sections 8(a) and 8(b), any other stock into or for which such Preferred Stock may be converted or exchanged. 

“Purchase Price” means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the
relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Warrant pursuant to such exercise. 

“SEC” means the Securities and Exchange Commission. 

  
 2 

 “Warrant Coverage” means $395,000, plus, subject to and contingent
on the funding of the Third Term Loan Advance (as defined in the Loan Agreement) in accordance with the Loan Agreement, $296,250. 
  

	SECTION 	 2. TERM OF THE AGREEMENT. 

Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein (the
“Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending 10 years after the Effective Date. 
  

	SECTION	 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or
from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the
“Notice of Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three
(3) business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as
Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future exercises, if any. 

The Purchase Price may be paid at the Warrantholder’s election either (a) by cash or check, or (b) by surrender of all or a
portion of the Warrant for shares of Preferred Stock to be exercised under this Warrant and, if applicable, an amended Warrant representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”).
If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

 
  

					
	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Warrant (inclusive of shares of Preferred Stock surrendered to the Company in payment of the aggregate Exercise Price in connection with a Net
Issuance).
			
		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		  	B =	  	the Exercise Price.

  
 3 

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect
to each share of Preferred Stock: 
 (i) if the exercise is in connection with the Initial Public Offering, and if the
Company’s registration statement relating to the Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (A) the initial “Price to Public” of the Common
Stock specified in the final prospectus with respect to the Initial Public Offering and (B) the number of shares of Common Stock into which each share of Preferred Stock is then convertible; 

(ii) if the exercise is after, and not in connection with, the Initial Public Offering, then: 

(A) if the Common Stock is traded on a national securities exchange, the fair market value shall be deemed to be the prior day
closing price before the day the current fair market value of the securities is being determined; or 
 (B) if the Common
Stock is traded over-the-counter, the fair market value shall be deemed to be the prior day closing bid and asked price quoted on the NASDAQ system (or similar system)
before the day the current fair market value of the securities is being determined; 
 (iii) if at any time the Common Stock
is not listed on a national securities exchange or quoted in the over-the-counter market, the current fair market value of Preferred Stock shall be the product of
(x) the then-fair market value per share of Common Stock, as determined in good faith by its Board of Directors, and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such
exercise, unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Preferred Stock pursuant to such Merger Event. 

Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares and/or
other securities purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof 

(b) Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all shares of Preferred Stock subject
hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 3(a) (even if not
surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the
extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the
Warrantholder is to receive by reason of such automatic exercise. 

  
 4 

	SECTION 	 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred
Stock to provide for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the shares of Preferred
Stock issuable hereunder. 
  

	SECTION 	 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional
shares the Company shall make a cash payment therefor upon the basis of the then fair market value of one share of Preferred Stock. 
  

	SECTION 	 6. NO RIGHTS AS STOCKHOLDER. 

This Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of
the Warrant under this Agreement. 
  

	SECTION 	 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The Warrantholder’s initial
address, for purposes of such registry, is set forth below the Warrantholder’s signature on this Agreement. The Warrantholder may change such address by giving written notice of such changed address to the Company. 

 

	SECTION 	 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 

(a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so
that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of preferred stock or other securities or property (collectively, “Reference Property”) that the Warrantholder would
have received in connection with such Merger Event if Warrantholder had exercised this Warrant immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors and
reasonably acceptable to the Warrantholder) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement
(including adjustments of the Exercise Price, the ability of the Warrantholder to elect the class and series of Preferred Stock as set forth in the definition thereof, and adjustments to ensure that the provisions of this
Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue
to be applicable in their entirety, 

  
 5 

 
and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations
of this Agreement; provided that the foregoing assumption requirement shall not apply if the consideration to be paid for or in respect of the outstanding shares of Preferred Stock in such Merger Event consists solely of cash and/or
Marketable Securities (a “Liquid Sale”), in which case this Warrant shall, upon the closing of such Liquid Sale, automatically and without further action on the part of any party or other person, represent the right to receive, in
lieu of the shares of Preferred Stock, or other capital stock of the Company for which this Warrant is then exercisable, that are issuable hereunder as of immediately prior to the closing of such Liquid Sale, the consideration payable on or in
respect of such shares of Preferred Stock, or other capital stock of the Company for which this Warrant is then exercisable, in such Liquid Sale less the Purchase Price for all such shares of Preferred Stock (or other capital stock of the Company
for which this Warrant is then exercisable), such consideration to include both the consideration payable at the closing of such Liquid Sale and any deferred consideration payable on or in respect of such shares of Preferred Stock, or other capital
stock of the Company for which this Warrant is then exercisable, thereafter, if any, including, but not limited to, payments of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other
performance-based payments, and such consideration shall become payable to the Warrantholder as and when it is paid to the holders of the outstanding shares of Preferred Stock, or other capital stock of the Company for which this Warrant is then
exercisable (such aggregate consideration, the “Aggregate Liquid Sale Consideration”); provided, further, that in connection with a Liquid Sale where the Aggregate Liquid Sale Consideration would be less than the
aggregate Exercise Price in effect immediately prior to the consummation of such Liquid Sale, then this Agreement will automatically expire effective as of immediately prior to the consummation of such Liquid Sale. In connection with a Merger Event
and upon the Warrantholder’s written election to the Company, the Company shall cause this Agreement to be exchanged for the consideration that the Warrantholder would have received if the Warrantholder had chosen to exercise its right to have
shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this
Section 8(a) shall similarly apply to successive Merger Events. 
 (b) Reclassification of Shares. Except
for Merger Events subject to Sections 8(a) and 8(e), if the Company at any time shall, by combination, reclassification, exchange, conversion or subdivision of securities or otherwise, change any of the securities as
to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been
issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, conversion, subdivision or other change. The
provisions of this Section 8(b) shall similarly apply to any successive combination, reclassification, exchange, conversion, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares of Preferred Stock issuable hereunder shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased and the number of shares of Preferred Stock issuable hereunder shall be proportionately decreased. 

  
 6 

 (d) Dividends. If the Company at any time while this Agreement is outstanding and
unexpired shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise
Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination
by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of
Preferred Stock outstanding immediately after such dividend or distribution; or 
 (ii) make any other dividend or
distribution with respect to Preferred Stock (or stock into which the Preferred Stock is convertible), except any dividend or distribution specifically provided for in any other clause of this Section 8, then, in each such
case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Preferred Stock (or
other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the stockholders of the Company entitled to receive such dividend or distribution. 

(e) Antidilution Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the
Charter and shall be applicable with respect to the Preferred Stock issuable hereunder (for the avoidance of doubt, any waivers of antidilution adjustments with respect to the Preferred Stock effected from time to time in accordance with the terms
of the Charter shall be applicable with respect to the Preferred Stock issuable hereunder). The Company shall promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter applicable to the Preferred Stock
or any other securities for which this Warrant shall then be exercisable; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the Effective Date
unless such amendment, modification or waiver applies to all then outstanding shares of Preferred Stock in the same manner. In the event of any issuance by the Company of any of its stock or other equity security after the Effective Date of this
Agreement that results in the application of antidilution rights for the Preferred Stock purchasable hereunder, the Company shall provide the Warrantholder with notice of such issuance within ten (10) days following the closing of such
issuance, and the Company shall provide the Warrantholder with such information as the Warrantholder reasonably requests in connection with Warrantholder’s determination of the effect of such issuance on this Warrant. The Company shall provide
the Warrantholder with such information as is reasonably necessary for the Warrantholder to determine the effect of such issuances on this Warrant. For the avoidance of doubt, there shall be no duplicate antidilution adjustment pursuant to this
subsection (e), the foregoing subsection (d) and the Charter. 

  
 7 

 (f) Notice of Adjustments. If: (i) the Company shall declare any dividend or
distribution upon its stock, whether in stock, cash, property or other securities; (ii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (iii) the Company shall sell, lease, exclusively license or
otherwise transfer all or substantially all of its assets; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder:
(A) at least fifteen (15) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend or distribution (specifying the date on which the holders of Preferred Stock
shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, exclusive license or other transfer of all or
substantially all assets, dissolution, liquidation or winding up, at least fifteen (15) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be
entitled to exchange their Preferred Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company shall give the Warrantholder
at least fifteen (15) days’ written notice prior to the effective date of the registration statement therefor. 
 Each such written notice shall
set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the
adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given in accordance with Section 12(g).

 (g) Timely Notice. Failure to timely provide such notice required by Section 8(f) shall entitle the
Warrantholder to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by the Warrantholder. For purposes of this Section 8(g), and
notwithstanding anything to the contrary in Section 12(g), the notice period shall begin on the date the Warrantholder actually receives a written notice containing all the information required to be provided in such
Section 12(g). 
  

	SECTION 	 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and
validly reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of
any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws and pursuant to any agreements, including the Stockholder
Agreements (as defined below), that the Warrantholder may become a party to in connection with such exercise. The Company has made available to the Warrantholder true, correct and complete copies of that certain Eighth Amended and Restated
Investors’ Rights Agreement, dated on or about the Effective Date, by and among the Company and the other parties thereto (the “Rights Agreement”), that certain Seventh Amended and Restated Voting, Right of First Refusal and Co-Sale Agreement, dated on or about the Effective Date, by and among the Company and the other parties thereto (the “ROFR Agreement” and together with the Rights

  
 8 

 
Agreement, the “Stockholder Agreements”), its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon exercise of this Warrant shall be made
without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be
required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

(b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to the Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company.
This Agreement: (i) does not violate the Charter or the Company’s current bylaws; (ii) does not contravene any law or governmental rule, regulation or order applicable to the Company; and (iii) does not and will not contravene
any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which the Company is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company,
enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application affecting enforcement of creditors’ rights generally. 

(c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect
of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for any filing required by applicable state securities
law, which filings will be effective by the time required thereby. 
 (d) Issued Securities. All issued and outstanding shares of
Common Stock, Preferred Stock or any other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in
full compliance with all federal and state securities laws. In addition, as of the date immediately preceding the date of this Agreement: 

(i) The authorized capital of the Company consists of (A) 353,272,950 shares of Common Stock, of which 222,394 shares are
issued and outstanding, (B) 4,856,947 shares of Series 1 Convertible Participating Preferred Stock, of which 4,856,947 shares are issued and outstanding and are convertible into an aggregate of 4,856,947 shares of Common Stock at $1.15 per
share, (C) 32,172,860 shares of Series 2 Convertible Participating Preferred Stock, of which 29,272,426 shares are issued and outstanding and are convertible into an aggregate of 29,272,426 shares of Common Stock at $1.15 per share, (D) 63,500,000
shares of Series 3 Convertible Participating Preferred Stock, of which 60,996,836 shares are issued and outstanding and are convertible into an aggregate of 60,996,836 shares of Common Stock at $1.15 per share and (E) 197,175,000 shares of Series 4
Convertible Participating Preferred Stock, of which no shares are issued and outstanding and are convertible into an aggregate of no shares of Common Stock at $0.38 per share. 

  
 9 

 (ii) The Company has reserved 46,079,080 shares of Common Stock for issuance
under its Stock Option Plan(s), under which options to purchase 3,317,422 shares of Common Stock are outstanding. There are warrants outstanding to purchase an aggregate of 2,900,434 shares of Series 2 Convertible Participating Preferred Stock.
There are no other options, warrants, conversion privileges or, except as set forth in the ROFR Agreement, other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or
other securities of the Company. 
 (iii) No stockholder of the Company has preemptive rights to purchase new issuances of
the Company’s capital stock under the Charter. Certain stockholders of the Company have preemptive rights to purchase new issuances of the Company’s capital stock or other securities under the ROFR Agreement. 

(iv) The lowest issue price per share of Series 4 Convertible Preferred Stock purchased for new money investments in the
initial closing of the transactions under the Series 4 Preferred Stock Purchase Agreement dated December 29, 2017 was $0.38 per share, and the Company has no side letters or other arrangements with any investor providing for any discounts or
reductions to such per share price. 
 (e) Registration Rights. The Company agrees that the shares of Common Stock issued and issuable
upon conversion of the shares of Preferred Stock issued and issuable upon exercise of this Warrant, and, at all times (if any) when the Preferred Stock shall be Common Stock, the shares of Preferred Stock issued and issuable upon exercise of this
Warrant, shall have the “Piggyback” and S-3 registration rights pursuant to and as set forth in the Rights Agreement, as the same may be amended and/or restated from time to time, on a pari passu
basis with the holders of outstanding shares of Preferred Stock who are parties thereto. The provisions set forth in the Rights Agreement relating to such registration rights in effect as of the Effective Date may not be amended, modified or waived
without the prior written consent of the Warrantholder unless such amendment, modification or waiver affects the rights associated with the shares of Preferred Stock issued and issuable upon exercise hereof in the same manner as such amendment,
modification or waiver affects the rights associated with all outstanding shares of Preferred Stock whose holders are parties thereto. 
 (f)
Other Commitments to Register Securities. Except as set forth in this Agreement and the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act
any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (g) Exempt Transaction. Subject
to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of this Warrant, and the issuance of the Common Stock upon conversion of the Preferred Stock, will
each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

  
 10 

 (h) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock
issuable upon the exercise of this Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon the Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

(i) Information Rights. During the term of this Warrant, the Warrantholder shall be entitled to the information rights contained in
Sections 7.1(a) and (c) of the Loan Agreement, and Sections 7.1(a) and (c) of the Loan Agreement are hereby incorporated into this Agreement by this reference as though
fully set forth herein. 
  

	SECTION 	 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. The right to acquire Preferred Stock is being acquired for investment and not with a view to the sale or
distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of such rights or the Preferred Stock except pursuant to an effective registration statement or an exemption from the
registration requirements of the Act. 
 (b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable
upon exercise of this Warrant is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

(c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (d) Risk of No
Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the 1934 Act, or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering
the securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to
hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in
reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

  
 11 

 (e) Accredited Investor. The Warrantholder is an “accredited investor”
within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
  

	SECTION 	 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this
Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a
notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on
such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
  

	SECTION 	 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to
protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the Warrantholder
will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other person entitled to the benefit of this Agreement
requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this Agreement. 

(c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the
observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary in order to protect the rights of the
Warrantholder against impairment. 
 (d) Additional Documents. The Company, upon execution of this Agreement, shall provide the
Warrantholder with certified resolutions of the Company’s Board of Directors (i) authorizing the issuance of the Warrant and (ii) reserving for issuance, upon exercise of the Warrant, such number of shares of Preferred Stock as may
from time to time be issuable with respect to the Warrant hereunder and such number of shares of Common Stock as may from time to time be issuable upon conversion of such shares of Preferred Stock. The Company shall also supply documentation
reasonably necessary to evaluate whether to exercise this Warrant, 

  
 12 

 
including without limitation, (A) any merger/purchase/asset sale agreement and related documents and estimated payout allocations to each of the respective shareholders, warrant and option
holders in connection with a Merger Event, (B) the most recent capitalization tables, 409A valuations (if any), and board determination of share value (including any waterfall or per share allocations provided to the share/unitholders), and
(C) most recent Charter. 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and
the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e),
attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency
proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 

(f) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g) Notices. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and
shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time
zone of the recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express
service or overnight mail delivery service; or (ii) the third (3rd) calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to
the party to be notified as follows: 
 If to the Warrantholder: 

HERCULES TECHNOLOGY III, L.P. 

Legal Department 
 Attention:
Chief Legal Officer and Anup Arora 
 400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile:
[***] 
 Telephone: [***] 

  
 13 

 With a copy to (which shall not constitute notice): 

Arnold & Porter Kaye Scholer LLP 

250 W. 55th Street, New York, NY 10019 

Attention: Michael Penney 

Facsimile: [***] 
 Telephone:
[***] 
 (i) If to the Company: 
 Intuity
Medical, Inc. 
 3500 W. Warren Ave. 

Fremont, CA 94538 
 Attention:
Chief Executive Officer, Chief Financial Officer 
 Telephone: [***] 

With a copy to (which shall not constitute notice): 

Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA
94025 
 Attention: Kathleen Wells 

Facsimile: [***] 
 Telephone:
[***] 
 Email: [***] 
 or to such other
address as each party may designate for itself by like notice. 
 (h) Entire Agreement; Amendments. This Agreement constitutes the
entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written
or oral, with respect to the subject matter hereof (including the Warrantholder’s proposal letter dated December 6, 2017). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto.

 (i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (j) No Strict Construction. The parties hereto have participated jointly
in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (k) No Waiver. No omission
or delay by the Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or
remedy to which the Warrantholder is entitled, nor shall it in any way affect the right of the Warrantholder to enforce such provisions thereafter. 

  
 14 

 (l) Survival. All agreements, representations and warranties contained in this
Agreement or in any document delivered pursuant hereto shall be for the benefit of the Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(m) Governing Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by the Warrantholder in the State of California. Delivery of the Preferred Stock to the Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(n) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (i) consents to personal jurisdiction in Santa Clara County,
State of California; (ii) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (iii) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(iv) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance
with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any
other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (o)
Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to
apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND THE WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF
ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST THE WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY.
This waiver extends to all such Claims, including Claims that involve persons other than Company and the Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and the Warrantholder; and any
Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. 

  
 15 

 (p) Judicial Reference. If the waiver of jury trial set forth above is ineffective or
unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a
referee selected by the Presiding Judge of Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(q) Prejudgment Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent
jurisdiction identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are
otherwise subject to resolution by judicial reference. 
 (r) Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the
same instrument. 
 [Remainder of Page Intentionally Left Blank] 

  
 16 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

					
	COMPANY:	 	INTUITY MEDICAL, INC.
			
		 	By:	  	 /s/ Emory V. Anderson

		 	Name: Emory V. Anderson
		 	Title: President and Chief Executive Officer
		
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY III, L.P.,
		 	a Delaware limited partnership
			
		 	By:	  	Hercules Technology SBIC Management, LLC, its General Partner
			
		 	By:	  	Hercules Capital, Inc., its Manager
			
		 	By:	  	 /s/ Jennifer Choe

		 	Name:	  	Jennifer Choe
		 	Its:	  	Assistant General Counsel

  
 17 

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	 Intuity Medical, Inc. 

 

	(1)	 The undersigned Warrantholder hereby elects to purchase [    ] shares of the Series
[    ] Preferred Stock of Intuity Medical, Inc., pursuant to the terms of the Warrant Agreement dated December 29, 2017 (the “Agreement”) between Intuity Medical, Inc. and the Warrantholder, and [CASH
PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

 

	(2)	 Please issue a certificate or certificates representing said shares of Series [    ]
Preferred Stock in the name of the undersigned or in such other name as is specified below. 

  

	
	  

	(Name)
	
	  

	(Address)

  

	(3)	 By its execution below and for the benefit of the Company, Warrantholder hereby restates each of the
representations and warranties in Section 10 of the Warrant Agreement as of the date hereof. 

  

					
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY III, L.P.,
		 	a Delaware limited partnership
			
		 	By:	  	Hercules Technology SBIC Management, LLC, its General Partner
			
		 	By:	  	Hercules Capital, Inc., its Manager
			
		 	By:	  	
                     
    

		 	Name:	  	
                 

		 	Its:	  	              

  
 18 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The
undersigned Intuity Medical, Inc., a Delaware corporation, hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology III, L.P., to purchase [____] shares of the Series [____] Preferred Stock of Intuity Medical, Inc.,
pursuant to the terms of the Warrant Agreement by and between Hercules Technology III, L.P. and Intuity Medical, Inc., dated December 29, 2017 (the “Agreement”), and further acknowledges that [__] shares remain subject to
purchase under the terms of the Agreement. 
  

					
	COMPANY:	  	INTUITY MEDICAL, INC.
			
		  	By:	  	
                     
        

		  	Name:	  	  

		  	Its:	  	  

  
 19 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign
the foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

	
	  

	(Please Print)

	
	
	whose address is                                  
                                         
                                         
                                         
                                         
                     

	
	
	  

  

	
	Dated:                                     
                                         
              
	
	Holder’s Signature:                                 
                                       
	
	Holder’s Address:                                 
                                         
  

  

	
	Signature Guaranteed:                                 
                                         
                                         
                                         
                                         
               

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without
alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]